R. Colclough, R. Wagstaff, S. Rees, K. Breese, C. Nicholls, S. Porter, G. Reeves, S. Gompertz
{"title":"P129数字时代的正确选择——对早期支持出院服务的健全患者选择","authors":"R. Colclough, R. Wagstaff, S. Rees, K. Breese, C. Nicholls, S. Porter, G. Reeves, S. Gompertz","doi":"10.1136/thorax-2021-btsabstracts.238","DOIUrl":null,"url":null,"abstract":"P130 Figure 1 Features of COVID-19 on the CT were very common in hospitalised patients and were related to all-cause mortality one year following hospitalisation Poster sessions A136 Thorax 2021;76(Suppl 2):A1–A205 on N ovem er 9, 2021 by gest. P rocted by coright. httphorax.bm jcom / T hrax: frst pulished as 10.113orax-2021-B T S abscts.239 on 8 N ovem er 221. D ow nladed fom CTT; 78 (25%) had consolidation and 274 (88%) had PE (figure 1). Patients from Asian, Black and Other ethnic minority groups had a higher prevalence and severity of multifocal ground glass changes on CTT compared to those from White groups (severe ground glass changes for White: 15 [6%]. Asian: 6 [14%], Black 2 [11%], Other 8 [47%], p<0.001). After one year, 104 (33%) patients died. On univariable analysis, multifocal ground glass changes and consolidation were related to all-cause mortality at one year. In a model consisting of age; ethnicity; gender; number of comorbidities; admission National Early Warning Score-2; admission lymphocyte count; C-reactive protein and urea, the addition of worsening ground glass changes on CTT were related to all-cause mortality at one year (aHR: 1.29, 95% CI 1.08–1.55, p=0.005 and Figure) and boosted the model’s cumulative discrimination (Harrell’s c statistic 0.75 from 0.69, p<0.001). Conclusion Evidence of COVID-19 pneumonia on CTT is more common and severe in patients from ethnic minority groups and is independently associated with worse prognosis following hospitalisation. P131 THE DEGREE OF ACUTE RESPIRATORY SUPPORT WITH COVID-19 PNEUMONIA, SMOKING STATUS ON ADMISSION AND NON-RESOLVING CT FEATURES AT THREE MONTHSARE THERE LINKS? H Karimzadeh, R Penfold, U Nnajiuba, A Wight.Wirral Lung Unit, Wirral University Teaching Hospital NHS Foundation Trust, Birkenhead, UK 10.1136/thorax-2021-BTSabstracts.240 Introduction and Objectives BTS guidelines suggest radiological follow up at 12 weeks for patients with COVID-19 associated pneumonia. It is suggested development of post-covid fibrotic changes is more prevalent with severity of illness. We compared illness severity based on maximal respiratory support with non-resolving changes on CT imaging at >12 weeks. Smoking status at time of admission was also collected. Methods Retrospective analysis of COVID-19 patients surviving to follow up identified either by CVCX1 coded CXR or CVCX2 coded CXR and positive PCR between March 2020January 2021. This identified 912 patients reviewed at 12 weeks with CXR ± CT imaging. 50/912 patients (5.5%) had evidence of either established fibrotic change or ongoing pneumonitis on CT. Imaging was reviewed by radiologist using suggested scoring system for Covid-19 follow-up 2 based on sum of 0–5 severity in 5 lobes (total 0–25) for markers of fibrosis/pneumonitis. Results Comparison is shown in table 1. All patients requiring more than 60% oxygen therapy received advanced respiratory support. 10/50 patients (20%) required no supplementary oxygen and 6/10 were not admitted to hospital. Comparison mean fibrosis score; IPPV-18.6, CPAP/HFNO-9.23, RA8.5. There were no current smokers in the follow-up cohort, 24 ex-smokers. Conclusions We noted significant risk for developing postCovid pneumonic fibrotic changes even in clinically mild cases. With SpO2 at times of peak incidence being main indicator for CXR and/or admission we surmise there may be a significant unrecognized population without an initial CXR to prompt follow-up. It is not clear whether these patients will develop significant symptoms to prompt future investigations and what impact this might have. No patients developing ongoing CT changes were current smokersa topic we suggest for further study and correlation. REFERENCES 1. McGroder CF, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax 29 April 2021. doi:10.1136/thoraxjnl-2021-217031 2. Xiaoyu Han, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021;299:1, E177–E186. P132 INTERMEDIATE FOLLOW UP OF RADIOLOGICAL INTERSTITIAL CHANGES FOR COVID-19 PATIENTS OVER THE FIRST YEAR POST DISCHARGE: A LONGITUDINAL STUDY JC Gates, A Draper, J Moser, J Arberry, D Jajbhay, J Panaguiton, E Yarham, YE Ong, R Aul. St George’s Hospital, London, UK 10.1136/thorax-2021-BTSabstracts.24","PeriodicalId":363081,"journal":{"name":"Improving care pathways in adults and children","volume":"554 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"P129 Getting it right in a digital age – robust patient selection to an early supported discharge service\",\"authors\":\"R. Colclough, R. Wagstaff, S. Rees, K. Breese, C. Nicholls, S. Porter, G. Reeves, S. Gompertz\",\"doi\":\"10.1136/thorax-2021-btsabstracts.238\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"P130 Figure 1 Features of COVID-19 on the CT were very common in hospitalised patients and were related to all-cause mortality one year following hospitalisation Poster sessions A136 Thorax 2021;76(Suppl 2):A1–A205 on N ovem er 9, 2021 by gest. P rocted by coright. httphorax.bm jcom / T hrax: frst pulished as 10.113orax-2021-B T S abscts.239 on 8 N ovem er 221. D ow nladed fom CTT; 78 (25%) had consolidation and 274 (88%) had PE (figure 1). Patients from Asian, Black and Other ethnic minority groups had a higher prevalence and severity of multifocal ground glass changes on CTT compared to those from White groups (severe ground glass changes for White: 15 [6%]. Asian: 6 [14%], Black 2 [11%], Other 8 [47%], p<0.001). After one year, 104 (33%) patients died. On univariable analysis, multifocal ground glass changes and consolidation were related to all-cause mortality at one year. In a model consisting of age; ethnicity; gender; number of comorbidities; admission National Early Warning Score-2; admission lymphocyte count; C-reactive protein and urea, the addition of worsening ground glass changes on CTT were related to all-cause mortality at one year (aHR: 1.29, 95% CI 1.08–1.55, p=0.005 and Figure) and boosted the model’s cumulative discrimination (Harrell’s c statistic 0.75 from 0.69, p<0.001). Conclusion Evidence of COVID-19 pneumonia on CTT is more common and severe in patients from ethnic minority groups and is independently associated with worse prognosis following hospitalisation. P131 THE DEGREE OF ACUTE RESPIRATORY SUPPORT WITH COVID-19 PNEUMONIA, SMOKING STATUS ON ADMISSION AND NON-RESOLVING CT FEATURES AT THREE MONTHSARE THERE LINKS? H Karimzadeh, R Penfold, U Nnajiuba, A Wight.Wirral Lung Unit, Wirral University Teaching Hospital NHS Foundation Trust, Birkenhead, UK 10.1136/thorax-2021-BTSabstracts.240 Introduction and Objectives BTS guidelines suggest radiological follow up at 12 weeks for patients with COVID-19 associated pneumonia. It is suggested development of post-covid fibrotic changes is more prevalent with severity of illness. We compared illness severity based on maximal respiratory support with non-resolving changes on CT imaging at >12 weeks. Smoking status at time of admission was also collected. Methods Retrospective analysis of COVID-19 patients surviving to follow up identified either by CVCX1 coded CXR or CVCX2 coded CXR and positive PCR between March 2020January 2021. This identified 912 patients reviewed at 12 weeks with CXR ± CT imaging. 50/912 patients (5.5%) had evidence of either established fibrotic change or ongoing pneumonitis on CT. Imaging was reviewed by radiologist using suggested scoring system for Covid-19 follow-up 2 based on sum of 0–5 severity in 5 lobes (total 0–25) for markers of fibrosis/pneumonitis. Results Comparison is shown in table 1. All patients requiring more than 60% oxygen therapy received advanced respiratory support. 10/50 patients (20%) required no supplementary oxygen and 6/10 were not admitted to hospital. Comparison mean fibrosis score; IPPV-18.6, CPAP/HFNO-9.23, RA8.5. There were no current smokers in the follow-up cohort, 24 ex-smokers. Conclusions We noted significant risk for developing postCovid pneumonic fibrotic changes even in clinically mild cases. With SpO2 at times of peak incidence being main indicator for CXR and/or admission we surmise there may be a significant unrecognized population without an initial CXR to prompt follow-up. It is not clear whether these patients will develop significant symptoms to prompt future investigations and what impact this might have. No patients developing ongoing CT changes were current smokersa topic we suggest for further study and correlation. REFERENCES 1. McGroder CF, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax 29 April 2021. doi:10.1136/thoraxjnl-2021-217031 2. Xiaoyu Han, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021;299:1, E177–E186. P132 INTERMEDIATE FOLLOW UP OF RADIOLOGICAL INTERSTITIAL CHANGES FOR COVID-19 PATIENTS OVER THE FIRST YEAR POST DISCHARGE: A LONGITUDINAL STUDY JC Gates, A Draper, J Moser, J Arberry, D Jajbhay, J Panaguiton, E Yarham, YE Ong, R Aul. St George’s Hospital, London, UK 10.1136/thorax-2021-BTSabstracts.24\",\"PeriodicalId\":363081,\"journal\":{\"name\":\"Improving care pathways in adults and children\",\"volume\":\"554 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Improving care pathways in adults and children\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/thorax-2021-btsabstracts.238\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Improving care pathways in adults and children","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/thorax-2021-btsabstracts.238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
P130图1 COVID-19的CT特征在住院患者中非常常见,并且与住院后一年的全因死亡率相关海报会议A136 Thorax 2021;76(补充2):2021年9月9日A1-A205。P由赖特保护。httphorax。[jj.com / thrax]首次发表为10.113orax-2021-B T S选集。8n上239比上221。从CTT加入;78例(25%)有实变,274例(88%)有PE(图1)。与白人患者相比,亚洲、黑人和其他少数民族患者CTT多灶磨玻璃病变的患病率和严重程度更高(白人患者磨玻璃病变严重:15例[6%])。亚洲:6周[14%],黑人2周[11%],其他8周[47%],共12周。还收集了入院时的吸烟状况。方法回顾性分析2020年3月至2021年1月期间通过CVCX1编码CXR或CVCX2编码CXR和阳性PCR鉴定的COVID-19幸存随访患者。本研究确定了912例在12周时进行CXR±CT成像的患者。50/912例患者(5.5%)在CT上有明确的纤维化改变或持续的肺炎的证据。影像学检查由放射科医生使用建议的Covid-19随访评分系统2进行审查,该评分系统基于纤维化/肺炎标志物的5个叶(总0-25)0-5严重程度的总和。结果比较见表1。所有需要60%以上氧气治疗的患者均接受了高级呼吸支持。10/50患者(20%)不需要补充氧气,6/10患者未住院。比较平均纤维化评分;Ippv-18.6, cpap / hfno-9.23, ra8.5。随访队列中没有吸烟者,24名戒烟者。结论我们注意到即使在临床轻度病例中,发生covid后肺炎纤维化改变的风险也很大。由于SpO2是CXR和/或入院的主要指标,我们推测可能有大量未被识别的人群没有进行初始CXR以及时随访。目前尚不清楚这些患者是否会出现重大症状,以促使未来的调查,以及这可能会产生什么影响。目前没有出现持续CT改变的患者是吸烟者,我们建议进一步研究和相关性。引用1。McGroder CF等。COVID-19后4个月的肺纤维化与疾病严重程度和血液白细胞端粒长度相关。2021年4月29日。doi: 10.1136 / thoraxjnl - 2021 - 217031 2。韩小雨,等。重症肺炎后随访6个月胸部CT表现。中华放射学杂志(英文版);2009;39(1):557 - 557。J . Gates, A . Draper, J . Moser, J . Arberry, D . Jajbhay, J . Panaguiton, E . Yarham, YE Ong, R . Aul。24 .英国伦敦圣乔治医院,10.1136/thorax-2021- btsabstract
P129 Getting it right in a digital age – robust patient selection to an early supported discharge service
P130 Figure 1 Features of COVID-19 on the CT were very common in hospitalised patients and were related to all-cause mortality one year following hospitalisation Poster sessions A136 Thorax 2021;76(Suppl 2):A1–A205 on N ovem er 9, 2021 by gest. P rocted by coright. httphorax.bm jcom / T hrax: frst pulished as 10.113orax-2021-B T S abscts.239 on 8 N ovem er 221. D ow nladed fom CTT; 78 (25%) had consolidation and 274 (88%) had PE (figure 1). Patients from Asian, Black and Other ethnic minority groups had a higher prevalence and severity of multifocal ground glass changes on CTT compared to those from White groups (severe ground glass changes for White: 15 [6%]. Asian: 6 [14%], Black 2 [11%], Other 8 [47%], p<0.001). After one year, 104 (33%) patients died. On univariable analysis, multifocal ground glass changes and consolidation were related to all-cause mortality at one year. In a model consisting of age; ethnicity; gender; number of comorbidities; admission National Early Warning Score-2; admission lymphocyte count; C-reactive protein and urea, the addition of worsening ground glass changes on CTT were related to all-cause mortality at one year (aHR: 1.29, 95% CI 1.08–1.55, p=0.005 and Figure) and boosted the model’s cumulative discrimination (Harrell’s c statistic 0.75 from 0.69, p<0.001). Conclusion Evidence of COVID-19 pneumonia on CTT is more common and severe in patients from ethnic minority groups and is independently associated with worse prognosis following hospitalisation. P131 THE DEGREE OF ACUTE RESPIRATORY SUPPORT WITH COVID-19 PNEUMONIA, SMOKING STATUS ON ADMISSION AND NON-RESOLVING CT FEATURES AT THREE MONTHSARE THERE LINKS? H Karimzadeh, R Penfold, U Nnajiuba, A Wight.Wirral Lung Unit, Wirral University Teaching Hospital NHS Foundation Trust, Birkenhead, UK 10.1136/thorax-2021-BTSabstracts.240 Introduction and Objectives BTS guidelines suggest radiological follow up at 12 weeks for patients with COVID-19 associated pneumonia. It is suggested development of post-covid fibrotic changes is more prevalent with severity of illness. We compared illness severity based on maximal respiratory support with non-resolving changes on CT imaging at >12 weeks. Smoking status at time of admission was also collected. Methods Retrospective analysis of COVID-19 patients surviving to follow up identified either by CVCX1 coded CXR or CVCX2 coded CXR and positive PCR between March 2020January 2021. This identified 912 patients reviewed at 12 weeks with CXR ± CT imaging. 50/912 patients (5.5%) had evidence of either established fibrotic change or ongoing pneumonitis on CT. Imaging was reviewed by radiologist using suggested scoring system for Covid-19 follow-up 2 based on sum of 0–5 severity in 5 lobes (total 0–25) for markers of fibrosis/pneumonitis. Results Comparison is shown in table 1. All patients requiring more than 60% oxygen therapy received advanced respiratory support. 10/50 patients (20%) required no supplementary oxygen and 6/10 were not admitted to hospital. Comparison mean fibrosis score; IPPV-18.6, CPAP/HFNO-9.23, RA8.5. There were no current smokers in the follow-up cohort, 24 ex-smokers. Conclusions We noted significant risk for developing postCovid pneumonic fibrotic changes even in clinically mild cases. With SpO2 at times of peak incidence being main indicator for CXR and/or admission we surmise there may be a significant unrecognized population without an initial CXR to prompt follow-up. It is not clear whether these patients will develop significant symptoms to prompt future investigations and what impact this might have. No patients developing ongoing CT changes were current smokersa topic we suggest for further study and correlation. REFERENCES 1. McGroder CF, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax 29 April 2021. doi:10.1136/thoraxjnl-2021-217031 2. Xiaoyu Han, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021;299:1, E177–E186. P132 INTERMEDIATE FOLLOW UP OF RADIOLOGICAL INTERSTITIAL CHANGES FOR COVID-19 PATIENTS OVER THE FIRST YEAR POST DISCHARGE: A LONGITUDINAL STUDY JC Gates, A Draper, J Moser, J Arberry, D Jajbhay, J Panaguiton, E Yarham, YE Ong, R Aul. St George’s Hospital, London, UK 10.1136/thorax-2021-BTSabstracts.24